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Abstract: Parkinson’s disease (PD) is a progressively debilitating neurodegenerative disease
characterized by α-synucleinopathy, which involves all districts of the brain-gut axis, including
the central, autonomic and enteric nervous systems. The highly bidirectional communication
between the brain and the gut is markedly influenced by the microbiome through integrated
immunological, neuroendocrine and neurological processes. The gut microbiota and its relevant
metabolites interact with the host via a series of biochemical and functional inputs, thereby affecting
host homeostasis and health. Indeed, a dysregulated microbiota-gut-brain axis in PD might lie at
the basis of gastrointestinal dysfunctions which predominantly emerge many years prior to the
diagnosis, corroborating the theory that the pathological process is spread from the gut to the brain.
Toll-like receptors (TLRs) play a crucial role in innate immunity by recognizing conserved motifs
primarily found in microorganisms and a dysregulation in their signaling may be implicated in
α-synucleinopathy, such as PD. An overstimulation of the innate immune system due to gut dysbiosis
and/or small intestinal bacterial overgrowth, together with higher intestinal barrier permeability,
may provoke local and systemic inflammation as well as enteric neuroglial activation, ultimately
triggering the development of alpha-synuclein pathology. In this review, we provide the current
knowledge regarding the relationship between the microbiota-gut–brain axis and TLRs in PD. A better
understanding of the dialogue sustained by the microbiota-gut-brain axis and innate immunity via
TLR signaling should bring interesting insights in the pathophysiology of PD and provide novel
dietary and/or therapeutic measures aimed at shaping the gut microbiota composition, improving
the intestinal epithelial barrier function and balancing the innate immune response in PD patients,
in order to influence the early phases of the following neurodegenerative cascade.
Keywords: enteric microbiota; brain-gut axis; Parkinson’s disease; toll-like receptors; innate
immunity; central nervous system; enteric nervous system; gastrointestinal dysfunctions; probiotics;
pharmacological treatment; α-synuclein; gut dysbiosis; neurons; microglia; glial cells; intestinal
barrier permeability
1. Introduction
Parkinson’s disease (PD) is acknowledged as the second most common neurodegenerative
disorder, estimated to affect 1–2 per 1000 of the population worldwide [1]. About seven to ten
million people in the world suffer from PD [2]. This figure is expected to double in the near future,
circa 2030, due to aging of the population [3]. The etiology of PD still remains unclear. However,
the slow progression of the disease evolves years before the diagnosis is ascertained, involving various
neuroanatomical areas, arising from an assortment of genetic and environmental factors, and exhibiting
a large array of debilitating symptoms. From a histopathological perspective, PD is hallmarked by
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a distinctive depauperation of dopaminergic neurons in the substantia nigra pars compacta (SNc)
with consequent dopamine deficiency within the striatum and by the manifestation of intracellular
eosinophilic inclusions, the so called Lewy bodies and Lewy neurites in the remaining neurons.
Lewy pathology is characterized by intracellular insoluble aggregates of misfolded α-synuclein and
implicates not only the brain but is also widespread in the spinal cord and peripheral nervous system,
including sympathetic ganglia, enteric nervous system (ENS), salivary glands, adrenal medulla, vagus
nerve, cutaneous nerves and the sciatic nerve [4–6]. The progressive dopamine deficit in the basal
ganglia determines the characteristic parkinsonian triad of motor symptoms—rigidity, bradykinesia
and tremor. However, other significant non-motor symptoms have been receiving increasing attention
for the more negative impact in the quality of life of PD patients in comparison to motor symptoms.
These non-motor symptoms involve neuropsychiatric disorders (e.g., cognitive impairment, depression,
apathy, psychosis), sleep disturbances, sensory alterations (pain, olfactory impairment), and the
common gastrointestinal (GI) dysfunction reported by more than 80% of PD patients [7]. The first-line
intervention in PD management is the administration of dopamine modulators even if they can exert
serious side effects, produce limited benefits on alleviating non-motor disturbances and often fail to be
effective in the later stages of PD [6–8].
In the last decade, emerging evidence has revealed the presence of an intense dialogue between the
brain and the GI system, the so-called brain-gut axis. Disruption of this complex relationship has been
shown to be associated to the pathogenesis of several disorders, ranging from irritable bowel syndrome
(IBS), liver disease and chronic abdominal pain syndromes, to depression, anxiety, autism spectrum
disorders, dementia and PD. The brain-gut (or gut-brain axis) crosstalk can occur in a bidirectional
fashion: firstly, through a gut quiver on central nervous system (CNS) activities (e.g., changes in
mood, cognition or perception due to functional GI disorders [9,10], or subsequent to the release of gut
hormones [11], or following serious GI inflammatory diseases such as acute pancreatitis [12–14]);
secondly, through a central quiver on gut activities (e.g., stress-induced GI dysfunction [15]).
Indeed, a common alignment of both brain and gut can be identified in neurobiological disorders
(e.g., neurodegeneration or gliosis) [16].
Traditionally, the brain-gut axis was viewed as a flux of information, mediated by neurohormones
and inflammatory factors, travelling between the central, autonomic and enteric nervous systems
(CNS, ANS and ENS, respectively) with the concurrent participation of the neuroendocrine and
neuroimmune systems.
Several studies have focused on the role of the CNS in modulating the intestinal inflammation
through both parts of the ANS, the sympathetic and parasympathetic nervous system [17,18].
The inflammatory state of peripheral tissues is conveyed to the brain through afferent nerves which in
turn suppress cytokine production, improve intestinal barrier integrity and limit gut inflammation [18].
Recent studies performed in animal models of acute and chronic pancreatitis have shown that the
stimulation of primary afferent capsaicin-sensitive neurons or treatment with peptides (e.g., calcitonin
gene-related peptide) before the exposure to harmful factors, can activate an adaptive mechanism
called “preconditioning” which is able to reduce pancreatitis development [19–21]. Sensory neurons are
involved in gastroprotection and regulation of visceral blood flow and their stimulation by capsaicin
can potentially inhibit the progression of inflammation, by improving the endogenous release of nitric
oxide (NO) and thus the pancreatic blood flow [22–24]. In recent years, several preclinical studies
highlighted that certain psychoactive molecules can modulate the endocannabinoid system in the gut
and possibly impact the pathogenesis of inflammatory bowel disease, as well as its extra intestinal
manifestations such as pancreatitis [25,26]. It has been demonstrated by Warzecha et al. [25] that
anandamide reduces mucosal oxidative stress, inhibits the inflammatory process and preserves the
integrity of gastric mucosa in stress-induced gastric ulcers [25]. These effects are partly mediated
by capsaicin-sensitive sensory nerves [25] and, in the case of acute pancreatitis, the protective action
of anandamide depends on the phase of the inflammation [27,28]. Thus, the modulation of the
endocannabinoid system may be useful to treat gut-brain motor dysfunction in PD.
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Changes in the ANS occurred in conjunction with intestinal inflammation, however, disorders
such as IBS are also linked to inflammatory abnormalities of the ENS [17]. The ENS is the largest
nervous system outside the CNS, which autonomously regulates numerous functions of the GI tract,
either independently through neuro-glial circuits in the myenteric and submucosal plexus, or by
input of sympathetic and parasympathetic pathways to/from the brain. The enteric neurons and
glial cells form a vast communication network in close relationship with the gut microbiota and thus
the ENS can easily be affected by microbiome alterations and be involved in GI disorders as well
as in neurodegenerative diseases. Therefore, the ENS could represent an entry point for pathogens
or—conversely—for therapeutic interventions based on diet and/or commensal microbes-derived
molecules [29].
Lately, it is becoming increasingly clear that a third player, such as the gut microbiota,
can significantly influence the gut-brain crosstalk, having a marked impact on digestive processes,
immune responses, emotional status, perception and cognitive functions [16]. The microbiota-gut-brain
axis has attracted much attention regarding the pathogenesis of PD, in which GI dysfunction appears
about twenty years before motor impairments. Although PD patients manifest both gut dysmotility
and altered microbial composition, it is still unclear which condition comes first and what role the gut
and the gut microbiota have in PD progression.
In addition to maintaining gut homeostasis and several essential host physiological functions,
the gut microbiota is a producer of an assortment of Toll-like receptor (TLR) ligands, which can exert
proinflammatory effects under certain conditions. Despite microbial-derived components being potent
TLR ligands, the gut has a high tolerance to TLR ligands because epithelial cells express minimal TLRs
under physiological conditions [30]. In contrast, altered gut microbiota and disrupted gut epithelial
barrier activate TLRs which in turn trigger downstream signaling pathways, promoting inflammation
and oxidative stress in both the gut and brain of PD patients. Thus, gut microbiota and TLRs could
represent potential targets for PD treatment.
The exact mechanisms by which gut microbiota contribute to PD are still poorly understood,
despite the role of gut microbiota in the development of PD being well documented. Here, we first
describe the functional aspects of gut microbiota observed in PD. Then, we review the role of TLRs
associated with PD and their potential as a new target of dietary and/or therapeutic interventions.
2. Microbiota-Gut-Brain Axis and Host Health
Over the last decade, an increasing amount of literature has focused on the codevelopment of the
gut microbiota with the human host since birth and on their mutual shaping clearly relying on the
host genome, nutrition and lifestyle [31]. While the association of neuropsychiatric disorders with GI
disturbances dates back to Hippocrates, a clear demonstration of the essential cooperation between
brain and microbes was first described by the impressive amelioration of symptoms in patients
affected by hepatic encephalopathy following treatment with nonadsorbable oral antibiotics [32].
The gut microbiota is now being referred to as a new organ or an emergent system, which comprises
a number of microorganisms (bacteria, archaea, fungi, and viruses) comparable to the number of
cells residing in the human body [33]. In particular, the enteric microbiota, distributed along the
human GI tract, displays similar results in terms of relative abundance and distribution between
healthy adults, although the microbe profile is quite stable and unique for each individual, and can be
considered a personal microbic fingerprint or enterotype [34]. Firmicutes and Bacteriodetes are the most
dominant phyla (about 51% and 48%, respectively), with Actinobacteria (including the Bifidobacteria
genera), Cyanobacteria, Lentisphaerae, Fusobacteria, Spirochaetes, Proteobacteria, and Verrucomicrobia phyla
existing in relatively low abundance [35]. Although a relative consistency in microbial composition in
healthy people is usually maintained over time, small daily variations are found in each individual
unless exposed to disrupting agents or conditions, such as antibiotics, colonization by foreign
commensal microbes, marked changes in diet or lifestyle, or infectious or noninfectious disease [36–38].
The magnitude and the length of the disruption might affect the capability of microbiota to recover
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and return to the original composition once the dysfunction is resolved, however repeated harmful
stimuli will weaken its recovery with potential downstream outcomes on host physiology [38].
Aging is a critical window for not only the gut and brain function but also for the composition of
enteric microbiota that in turn may have serious consequences on health integrity in these latter stages
of life [38].
The bidirectional dialogue between the gut and the brain involves different mechanisms, including
the enteric and central neural network, neuroendocrine-hypothalamic-pituitary-adrenal axis, immune
system, several neurotransmitters and neural regulators directly produced by gut bacteria, and barrier
paths such as intestinal mucosal barrier and blood-brain barrier. The enteric microbiota is implicated in
the upregulation of the local and systemic inflammatory response induced by lipopolysaccharides (LPS)
derived from pathogens and the related production of proinflammatory mediators. The dysregulation
of immune response to environmental and/or microbial agents is associated with the onset of
inflammatory bowel disease in genetically susceptible individuals [39]. On the other hand, exposition
to low amounts of LPS in early life can affect the ability of the immune cells to produce the cytokines,
increasing the resistance of the organism to systemic diseases such as pancreatic inflammation [40].
Gut dysbiosis and/or small intestinal overgrowth (SIBO) increase intestinal permeability and
bacterial translocation, determining an immune system’s overresponse and consequent systemic
and/or central nervous system (CNS) inflammation. Enteric bacterial cells possess the capacity
to produce numerous neuroactive molecules, such as serotonin, catecholamines, glutamate,
γ-amminobutyric acid (GABA) and short-chain-fatty acids (SCFAs) [41–43]. It has been proposed that
the variety of neurotransmitters, neuromodulators and neurohormones produced by microorganisms
are the “words” of a common language that enables a sophisticated synergic communication [44].
However, considering the extreme complexity of this communication network, it remains to be
determined whether microbial neurochemicals are generated at an adequate level in respect to host
production to exert any kind of effect, or can be delivered to central neurocircuits through systemic
circulation [41,42]. Although some reports indicate the ability of bacteria to modulate the level of
neurotransmitters through TLRs and heat-shock proteins [45], this form of interaction may occur
directly via neuroactive molecules.
Most of the functions of the GI tract are regulated by enteric neurons, hormones produced by
enteroendocrine cells, and cytokines synthesized in somatic cells [46]. Of note, more than 90% of
all serotonin in the body is synthesized in the gut by the enterochromaffin cells, an enteroendocrine
cell subtype, known to be involved in controlling gut motility, emesis, visceral hypersensitivity and
secretion [47]. Most enteric serotonin is tuned by gut microbiome whereas the circulating serotonin
is generally metabolized by the liver [48]. This neuroamine regulates a variety of physiological
processes at the periphery but, even if it cannot cross the brain blood barrier (BBB), can affect
central neurocircuits by interfering with vagal nerve activity and BBB permeability, thus indirectly
influencing brain functions [49]. Therefore, although the brain and the gut are the two major sources of
serotonin synthesis, physically separated by the BBB, from a biological point of view these pathways
are potentially not always distinct. In this respect, enteric bacteria can also produce neurotoxic
molecules (e.g., D-lactic, ammonia) and neurotoxins, (e.g., those produced by Clostridium perfringens,
Clostridium botulinum, Clostridium butyricum, Clostridium baratii, among others) and reach CNS being
transported via systemic circulation or through extrinsic afferent nerve fibers (i.e., vagal nerve
projections from the gut to the brainstem and spinal nerve projections from the gut to the spinal
cord), provoking neuronal injury [50,51]. In turn, the CNS can control the enteric microbiota
through adrenergic neurotransmission, primarily modulating intestinal motility and neuroimmune
crosstalk [52].
Most of the effects mediated by the gut microbiota or potential food-based therapeutic
interventions (e.g., probiotics, prebiotics, synbiotics) on CNS functionality have been shown to be
exerted through the modulation of vagal neurotransmission [53]. Likewise, microbial colonization
of the gut after birth and during infancy is markedly involved in the postnatal development and
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maturation of the host nervous, immune, and endocrine systems. Altogether these pieces of evidence
highlight the key role of microbiota-gut-brain axis in ensuring and protecting host health and its
involvement in a plethora of diseases ranging from stress-induced disorders to neurologic and
psychiatric disorders [53].
3. The Gastrointestinal System in Parkinson’s Disease
GI dysfunctions are generally experienced by most patients with PD and usually include
hypersalivation, dysphagia, delayed gastric emptying, nausea, constipation and altered bowel habits.
Disturbances in oral and pharyngeal swallowing have been shown in other neurological diseases,
such as amyotrophic lateral sclerosis, and manometric endoscopy of the upper GI tract was a useful
procedure for the assessment of the severity of deglutition disorders among these patients [54].
A higher prevalence of peptic ulcer and Helicobacter pylory (Hp) infection has been revealed
in PD patients. Hp infection is considered to be the most important factor responsible for the
development of gastroduodenal diseases, including active chronic gastritis, peptic ulcer disease
and gastric adenocarcinoma [55]. However, there is increasing evidence that Hp gastric infections are
potentially associated with several systemic extra-GI diseases such as cardiovascular, immunological
and inflammatory disorders (e.g., acute pancreatitis) [55].
Constipation is a major enteric dysfunction of PD and predates motor symptoms years before
the manifestation of the disease, making it one of the earliest biomarkers of the pathological process
that will ultimately emerge into PD [6]. The anomalies in gut functionality in PD may result from
both central and peripheral altered neurotransmission pathways. Even if until now the findings
of an impaired enteric neurotransmission are contradictory [56], a pathological hallmark of PD is
the distribution of α-synuclein pathology in olfactory bulbs and in both submucosal and mucosal
plexuses of gut ENS from esophagus to the rectal end. Braak et al. [57] have proposed that α-synuclein
deposition might begin in the olfactory bulbs or/and in the ENS by an unknown environmental toxin
and/or microbial pathogen and then proceed towards SNc and further sites in the CNS. Full truncal
vagotomy in PD patients resulted in decreased risk of PD progression compared to partial or no
vagotomy, suggesting an involvement of the vagus nerve as a conduit for the spreading of Lewy
bodies from ENS to CNS [58]. Moreover, it has been shown that toxins like pesticides (e.g., rotenone),
orally administered to mice, replicate the staging of PD-like pathology from ENS to CNS [35]. In this
preclinical model, the resection of sympathetic and parasympathetic nerves (i.e., hemivagotomy and
partial sympathectomy) prior to the oral exposure to rotenone prevented the spreading of PD-like
pathology from ENS to the previously connected central neurocircuits and delay the manifestation
of gut motor symptoms [59]. Considering that gut mucosa is in contact with environmental factors,
these findings support the concept that external triggers, including diet-derived molecules, toxins or
microbes, might have a major role in eliciting and spreading PD pathology, potentially in a milieu of
genetic vulnerability.
However, recent studies have suggested that the initiation of α-synuclein pathology in the GI
tract does not necessarily need a pathogenic or environmental trigger since it can be instigated by
enteric microbiota [60,61].
4. The Gut Microbiota in Parkinson’s Disease
Gut constipation, SIBO, increased intestinal permeability of the mucosal barrier and GI inflammation
are all symptoms closely interrelated to gut microbiota composition and microbial-derived metabolites.
In the early stages of PD, higher intestinal permeability, a condition known as leaky gut syndrome, has
been observed to be associated with enteric α-synuclein pathology [60]. Increased intestinal permeability,
due to a defective gut barrier function, facilitates the translocation of microorganisms (e.g., bacteria) and
microbial products (e.g., LPS), which, in turn, might initiate inflammation and oxidative stress, thereby
leading to α-synucleinopathy in the ENS [60]. Moreover, higher levels of gut-derived LPS can disrupt the
integrity of the BBB, promoting neuroinflammation and damage in SNc [62].
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Current evidence from different clinical studies has revealed that gut microbiota composition is
altered in PD patients and related to the clinical phenotype of the disease. Analysis of fecal samples
of PD subjects disclosed higher levels of Enterobacteriaceae, which were positively associated with the
degree of gait and postural instability [63], as well as a reduced abundance of the Prevotellaceae bacterial
family. Prevotellaceae are commensals bacteria, implicated in the production of mucin in the gut mucosal
layer, in the synthesis of neuroactive SCFAs (e.g., acetate, propionate, and butyrate) through fiber
fermentation, and in the release of thiamine and folate. Hence, the decreased levels of Prevotellaceae could
be related to reduced mucin synthesis and increased intestinal permeability, with consequent systemic
exposure to bacterial antigens and endotoxins [60], and potential development of α-synucleinopathy by
the disruption of clearance mechanisms of the intra- and extraneuronal protein by SCFA-dependent
modulation of gene expression [64].
Furthermore, the lower abundance of Prevotellaceae associated with an increase of Lactobacillaceae
has been linked to a reduction in the levels of gut hormone ghrelin, known to be involved in ensuring
physiological nigrostriatal dopamine activity [65]. Indeed, in PD patients an impaired postprandial
response to ghrelin has been reported [66].
A subsequent study demonstrated changes in both mucosal and fecal microbial compositions
of PD, such as a higher abundance in the putative, proinflammatory Proteobacteria of the genus
Ralstonia and a reduced level of bacteria from the genera Blautia, Coprococcus, and Roseburia, involved in
producing butyrate, a SCFA associated with anti-inflammatory properties [61]. Furthermore, decreased
concentrations in SCFA have also been evidenced in PD patients and could be related to the observed
impaired peristaltic regulation by the ENS and consequent gut dysmotility. At a genomic level,
PD microbiota owns more genes implicated in LPS biosynthesis and type III bacterial secretion systems
and a lower number of genes related to metabolism [61]. Although the role of gut microbiota in PD
is still at its infancy, a recent experimental work demonstrated that fecal microbiota transplant from
PD-donor accelerated the disease in genetically predisposed animals [67]. These findings advocate
that PD-associated factors in the host alter enteric microbiome, which in turn worsens PD pathology
and symptoms. Indeed, the enteric microbiota is implicated in the regulation of the local and systemic
inflammatory response induced by LPS and the production of proinflammatory mediators.
5. Toll-Like Receptors
Being the first line of defense against invading microbes, the innate immune system is vital in
early recognition of infection [68]. Innate immunity senses the presence of microorganisms through
a number of patter-recognition receptors (PRRs) [69], which specifically recognize evolutionarily
conserved molecular structures, denominated pathogen-associated molecular patterns (PAMPs),
widely expressed by a variety of infectious microbes, which are essential for their own survival [70].
Among the different PRRs, situated in both extracellular and intracellular milieu, TLRs are the most
interesting family of mammalian receptors, orthologs of the Toll receptors discovered in Drosophila
Melanogaster in 1988 [71]. Until now, thirteen TLRs have been identified in mammals, of which
a total of ten have been characterized in a variety of human tissue and cells, not only belonging to
the immune system and epithelial tissue but also to neurons and glial cells of both the peripheral
nervous system (PNS) and the CNS. The distribution of these immune sensors in the nervous system
highlights the ability of neural cells to mediate immune responses as well as their vital dependency
for development and homeostasis on TLRs signaling [72–76]. Indeed, TLRs are not only engaged by
PAMPs but also by a set of endogenous molecules generated during tissue damage (damage-associated
molecular patterns, DAMPs), activating firstly an acute immune response and, secondarily, tuning
the subsequent adaptive immune reaction. TLRs are further classified into subfamilies according to
the types of PAMPs or DAMPs that they recognize. The plasma membrane bound TLRs interact with
molecules composing the bacterial cell walls and membranes, such as lipopeptides, peptidoglycans
and glycolipids (TLR1/TLR2, TLR2/TLR6, TLR2/TLR10), fibronectin, lipopolysaccharides, and heat
shock proteins (TLR4), and flagellin (TLR5). On the contrary, the intracellular TLRs, expressed
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in cell endosomes, detect microbial nucleic acids, specifically viral double-strand RNAs (TLR3),
single-strand RNAs (TLR7 and TLR8), unmethylated CpG DNA (TLR9) [77]. TLR engagement activates
distinctive adaptor proteins, such as Myeloid differentiation primary response gene 88 (MyD88) or the
TIR- domain-containing adapter-inducing interferon-β (TRIF) pathway, to deliver signals to several
downstream pathways, comprising the nuclear factor-kappa B (NF-κB), mitogen-activated protein
kinases (MAPK), and/or interferon-regulatory factor (IRF) signaling pathways, which are pivotal for
the expression of a variety of gene products involved in inflammatory responses [77,78].
More and more studies have focused their attention on the role that TLRs may play in
neurodegeneration, considering that they are extensively expressed in immune and non-immune cells
and their expression can change not only during microbial infections but also in the presence of sterile
inflammation when the pathogens are absent.
6. TLRs in Parkinson’s Disease
Even if the exact etiology of sporadic PD is still to be found, increasing evidence suggest
that misfolded α-synuclein activates microglial cells in the SNc, promoting inflammation and
oxidative stress, leading to neurodegeneration. Extracellular misfolded, fibrillar α-synuclein, released
from neural cells or oligodendrocytes is recognized as PAMP or DAMP by microglial TLR2
(as heterodimer with TLR1), which in turn activates downstream pathways involving MyD88 and
NF-κB, triggering the production of TNF and IL-1β [79,80] and increasing selective expression of TLRs
in a localization- and time-dependent manner [81]. In in vitro studies TLR4 appears also to interact
with α-synuclein, triggering microglial responses, including α-synuclein uptake, proinflammatory
cytokine release, and oxidative stress promotion [82]. These findings were corroborated in an MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin)–induced murine model of PD where the genetic absence
of TLR4 signaling protected the mice from neurodegeneration, highlighting the primary role of TLR4 in
PD development [83]. Recent evidence in experimental models suggests a potential involvement
of the NLRP3 inflammasome, which can be modulated by TLRs signaling. Reduced caspase-1
activation and IL-1β release together with decreased loss of dopaminergic neurons in SNc was found
in NLRP3-deficient mice following MPTP insult [84]. Fibrillar α-synuclein has been reported to
engage TLR2 on human monocytes to prime the NLRP3 inflammasome [85]. Intriguingly, NLRP3
inflammasome inhibition was shown to be mediated by dopamine itself, although it is still unclear if
involvement of the inflammasome is antecedent to the degeneration of dopaminergic neurons or is the
result of neural depauperation [86]. The most convincing evidence for a role of TLRs in PD has been
found so far for TLR2 and TLR4. The contribution of TLR2 and TLR4 in PD might be a double-edged
sword: their activation in microglia can trigger neurotoxicity but on the other hand they might be
essential for clearing misfolded α-synuclein, hence being neuroprotective [87].
There is an increasing recognition of the involvement of TLRs in neuronal degeneration based
on the following pieces of evidence: (i) relevant cells of the nervous system express TLRs; (ii) TLRs
are activated by α-synuclein; (iii) their activation induces an inflammatory response that precedes
neuronal loss; (iv) halting TLRs engagement delays PD progression [88].
7. Microbiota-Gut-Brain-Axis and Toll-Like Receptor Signaling: Potential Implications in
Parkinson’s Disease
Aging determines alterations in responsivity of microglia, which may acquire a hyperreactive
phenotype (e.g., increased release of proinflammatory mediators and overexpression of cell surface
receptors) or an impaired condition with defective phagocytosis and clearance of misfolded protein
aggregates [89]. The acquired activated state of microglia in response to accumulation of abnormally
folded proteins and neurodegeneration is a process referred to as microglial priming, similar to
the newly emerging theory of “trained immunity” or “innate immune memory”, consisting in the
epigenetic and metabolic reprogramming of peripheral innate immune cells following an initial insult.
Indeed, macrophages derived from human hematopoietic stem and progenitor cells challenged with
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a TLR2 agonist during their differentiation and then inoculated in irradiated mice evidenced a tolerant
phenotype by releasing a reduced amount of inflammatory mediators and reactive oxygen species
in response to the inflammatory stimulus [90]. A growing body of evidence suggests that microglial
priming could be induced by epigenetic reprogramming as shown in trained immune cells [86].
Intestinal barrier function is impaired in patients with PD placing them at higher risk to be exposed to
microbial products [91], therefore the translocation of bacteria or bacterial-derived products such as
LPS (a TLR4 ligand) can induce a systemic inflammation, producing a more severe neurodegeneration.
Extracellular α-synuclein is recognized as a DAMP and TLR4 ablation has been shown to impair the
phagocytic response of microglia to α-synuclein with consequent accumulation of α-synuclein and
increased dopaminergic neurodegeneration in the SNc [92], highlighting the neuroprotective effect of
TLR4 signaling mediated through the clearance of α-synuclein, analogously to the suggested protective
role of TLR2 towards β-amyloid and α-synuclein.
It has been demonstrated that bacteria residing in the enteric microbiota produce extracellular
amyloid proteins. Curli, an amyloid protein synthesized by E. coli and S. typhimurium, has been
shown to enhance colonization and biofilm formation. Even if few studies have focused on the
presence of gut bacteria-derived amyloid proteins in the GI tract, the effect of bacterial amyloids on
α-synuclein accumulation or other molecular mechanisms associated to neurodegeneration is still
unknown [93]. The enteric microbiota is a huge antigenic load resident in the gut and confers marked
potential danger if not kept under continuous surveillance, such as under TLRs sensing. However,
the enteric commensal microbiota is required for the constant stimulation of the immune system
and TLR-mediated sensing of these microorganisms may play a dual role in disease development
as a source of both inflammatory and regulatory signals. In this respect, it is important to take into
account that the microbiota is also a source of biological active signaling molecules, immune mediators
and gut hormones. Some of those, including serotonin, purines, GABA and neurotrophic factors,
among others, have been shown to be involved in TLRs signaling [72,73,94–97]. Recent evidence has
also pointed out that microbiome-derived SCFAs finely tune microglial function, further suggesting
that microbiome-derived factors and nutrition are involved in controlling innate immune function in
neurodegeneration [98]. Intriguingly, the SCFA butyrate has been shown to increase TLR-dependent
responses by increasing their expression in a cellular model of human enteroendocrine L-cells [99].
The emerging evidence described above suggests the existence of a multifaceted TLR signaling
network that influences neural circuits and immune-mediated processes both in the gut and in the
brain. Further studies focused on discovering the enteric microbiota-derived factors responsible of
TLRs engagement and the consequent signaling outcomes of TLR activation in both the ENS and the
CNS will provide novel insights into the complex dialogue between the host and the microbiota in PD
and other relevant neurodegenerative disorders.
8. Potential Therapeutic Strategies
Recent research has gathered solid scientific evidence on the involvement of the GI tract in PD,
highlighting three important features. First, in animal models and human studies a clear association
has been put forward between the GI tract, gut inflammation, increased permeability, and PD. Second,
some dietary interventions appear to exert beneficial effects by modulating microbiota dysbiosis
toward a healthy state, reducing gut permeability, and/or decreasing oxidative stress and intestinal
inflammation. Third, since TLRs are dynamic guardians laying squarely between the environment and
the host, especially in the gut, any changes in TLR activity and expression might reduce or prevent the
incidence of developing diseases associated with an inflammatory status such as PD. Deciphering the
interactive dialogue that occurs between microorganisms in the gut and the activity of the immune
system regulated by TLRs is crucial for the discovery and development of compounds such as pharma-
and nutraceuticals (including syn-, pre- and probiotics), critical for preserving or restoring homeostasis
in the gut as well as in other host tissues.
Int. J. Mol. Sci. 2018, 19, 1689 9 of 19
None of the current medicines for PD show a beneficial influence on disease progression and
do not exert any effects on the microbiota-gut-brain axis to reduce the spread of Lewy pathology
or to alleviate motor and/or non-motor symptoms. However, traditional treatments for PD could
be combined with modulators of TLRs activity and/or food-based interventions to alleviate gut
dysfunction and symptoms, as well as positively influence the microbiota-gut-brain axis, thus reducing
GI dysbiosis and protecting the complex neuroglia network in both the ENS and CNS, [41,100–103].
8.1. Dietary Supplements
High levels of polyunsaturated fatty acids (PUFA), such as the omega-3 fatty acid
docosahexaenoic (DHA), have been shown to induce anti-inflammatory effects and reduce
mitochondrial dysfunction-mediated motor symptoms together with decreasing alpha-synuclein
accumulation and inflammation in PD animal models [102,104–107]. DHA inhibits, whereas
saturated fatty acids can activate, certain TLR-mediated pro-inflammatory signaling pathways.
DHA blocks the activation of TLR4 and TLR2/1 or TLR2/6 and other TLRs in an indirect manner,
targeting TLRs downstream pathways during the receptor dimerization process (e.g., lipid rafts) [108].
Overall these findings highlight the involvement of diet, such as the intake of saturated fatty
acids and DHA, in the modulation of TLR signaling pathways and related involvement in chronic
inflammation and subsequent risk of chronic diseases [108,109]. An in-vitro study has shown
that an extract of Panax notoginseng was able to suppress microglial activation and decrease the
release of inflammatory factors (IL-6 and TNF-α), suggesting the potential therapeutic utility in
slowing down PD progression [110]. The flavonoid silymarin, extracted from the seeds and fruit of
Silybum marianum, was found to exert neuroprotective effects in 6-OHDA-induced hemi-parkinsonian
rats, through the alleviation of nigral injury, the increase of anti-oxidant defenses and suppression of
TLR4 activation [111].
8.2. Probiotics
Probiotics are defined by the Food and Agriculture Organization of the United Nations and by
the World Health Organization (FAO/WHO) as “live microorganisms which, when administered in
adequate amounts, confer a health benefit on the host” [112]. The common benefit of probiotics on
gut microbiota originates from creating a more favorable GI environment and supporting a healthy
immune system [112]. Common probiotic functions are dependent on key core mechanisms found
in the shared architecture of the cell surface structures of most Gram-positive probiotics, such as
peptidoglycan, cell wall teichoic and lipoteichoic acid (LTA), and common but varying components
including exopolysaccharides, surface layer associated proteins (SLAPS), mucin-binding proteins
(MUBs), fibronectin binding proteins, and pili. These cell surface macromolecules in bacteria are
important factors in the beneficial microbiota-host dialogue, as they can interact directly with the
intestinal epithelium, mucus, and TLRs of the GI mucosa. The traditionally-used probiotics are from
the genera Lactobacillus and Bifidobacterium, which have been shown to enhance intestinal epithelial
integrity, protect from gut barrier disruption, regulate mucosal immune system and inhibit pathogenic
bacterial growth [112,113].
The most common probiotics belonging to the genera of Lactobacillus and Bifidobacterium are
Gram-positive bacteria and present a well-conserved core molecular architecture of peptidoglycan
and LTA, which are documented MAMPs interacting with TLR2/6 heterodimers. Modifications in
LTA structure or removal of LTA have elicited significant anti-inflammatory consequences observed in
mouse models of both colitis and colon cancer, suggesting that Gram-positive probiotics with decreased
expression of LTA are more prone to modulate the anti-inflammatory immunological consequences in
degenerative disorders [114].
The administration of probiotics has been shown to positively modulate brain function, including
stabilizing anxiety-like [115] and depression-like behavior [116], through the microbiota-gut-brain
axis [117]. Chronic administration of the Lactobacillus strain in healthy mice has been shown to reduce
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anxiety, depression and stress responses, and modulate the expression of central GABA receptors,
but only when the vagus nerve function was maintained intact, thereby highlighting the critical role of
autonomic transmission in the gut-brain axis [118]. Preclinical or clinical evidence on the beneficial
effects of probiotics in PD are still very limited. Ingestion of a fermented milk, supplemented with
multiple probiotic strains and prebiotic fiber, for four weeks was found to be superior to placebo
(a pasteurized, fermented, fiber-free milk) in improving constipation in patients with PD [119]. Another
study showed that fermented milk containing Lactobacillus casei strain Shirota for five weeks decreased
abdominal pain and bloating, and improved stool consistency [120].
A recent well-designed double-blinded randomized clinical trial (RCT) by Ojetti [121] showed
that Lactobacillus reuteri improved bowel movement frequency compared to placebo in patients with
functional constipation.
As mentioned above, gut dysfunction, including constipation and gut dysbiosis, contributes to
PD morbidity and participates in the pathological process of PD. Hence, the use of probiotics might
offer relief from the complications as well as decrease gut permeability, microbial translocation and
neuroinflammation in the ENS. Restoring gut function by administration of probiotics might lead to
better levodopa adsorption and improve behavioral and cognitive performance, which are common
symptoms in PD patients.
8.3. Prebiotics
Prebiotics are defined as “a selectively fermented ingredient that results in specific changes, in the
composition and/or activity of the gut microbiota, thus conferring benefit(s) upon host health” [122].
Examples of prebiotics are inulin, galacto-oligisaccharides (GOS), fructo-oligosaccharides (FOS) and
SCFAs. Considering that human enzymes are not able to digest complex carbohydrates, specific gut
microbes are involved in fermenting carbohydrates to SCFAs (i.e., acetate, proprionate and butyrate),
lactose, hydrogen, methane, and carbon dioxide, all metabolic products that, by lowering the pH of
the intestinal milieu, inhibit the survival and proliferation of pathogenic bacteria [103]. Prebiotic fibers
are well known for their beneficial effects on gut motility and immune function that are compromised
in PD patients [123]. The chronic administration of GOS and FOS for five weeks increased the levels
of brain-derived neurotrophic factor (BDNF) in the hippocampus of healthy rats, suggesting that
prebiotics can be implicated in ensuring CNS neuroprotection [124]. Although several studies have
shown the beneficial effect of prebiotics on GI function, immune response and neuroprotection, to date,
no clinical study has evaluated their use in PD which could be highly interesting in view of the fact
that PD patients have a lower abundance of SCFA-butyrate producing bacteria [61].
8.4. Antibiotics
Treating SIBO with antibiotics is a potential therapeutic strategy to improve the motor symptoms,
reduce intestinal bacterial contents as well as gas production. However, the therapy for SIBO is
challenging due to the absence of well-designed clinical trials in patients with or without PD and SIBO.
Moreover, there is still an absence of consensus on the exact definition of SIBO together with specific
diagnostic criteria that render the treatment complicated. Antibiotic therapy is usually a good option for
overcoming SIBO; however, considering that SIBO is caused by Gram-positive and -negative anaerobes
and aerobes, the choice of most appropriate antibiotic poses a challenge for gastroenterologists.
Rifaximin, a broad-spectrum nonadsorbable antibiotic, might be effective in the treatment of SIBO
for its action on Gram-negative and -positive aerobic and anaerobic bacteria [125]. While rifaximin is
the only antibiotic FDA-approved for treatment of diarrhea-predominant IBS and the most studied
antibiotic for the treatment of SIBO, no data on the use of rifaximin for treatment of SIBO in patients
with PD is currently available. A variety of other antibiotics (e.g., metronidazole, ciprofloxacin,
norfloxacin, amoxicillin-clavulanate, tetracycline, doxycycline and neomycin etc.) have been evaluated
for curing SIBO but the lower quality and sample power of most RCT have yielded no clear consensus
on the most appropriate type of antibiotic and related posology to be used. A growing body of evidence
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has suggested that minocycline elicits neuroprotective effects in PD, owing to its ability to restore gut
microbiota balance (reduction of Firmicutes/Bacteroidetes). Clinically, Phase II trials have assessed its
efficacy in PD patients and it is now under consideration for undertaking a Phase III trial [126].
8.5. TLRs Modulators
As mentioned above, TLRs appear to be associated with the neurodegenerative processes
characteristic of PD. TLR2 and TLR4 are potentially the most involved receptors in the progression
of PD. However, it was not clear until now whether the most beneficial outcome would be achieved
by stimulating TLR2 and/or TLR4 (e.g., favoring alpha-syn clearance) or to repress their signaling
to delimitate Lewy pathology as well as augment the levels of toxic factors such as proinflammatory
cytokines and reactive oxygen and nitrogen species. Considering that chronic administration of TLR2
and TLR4 ligands elicits microglial activation and a related marked release of toxic factors, current
knowledge in other pathologies advocates for their inhibition to prevent further tissue damage. Several
negative regulatory mechanisms have been developed to mitigate TLR signaling and ensure a balanced
immune response. To date, six levels of negative regulation have been revealed: (i) degradation of
TLR protein; (ii) down regulation of transcription mechanisms of TLR and related genes; (iii) post
transcriptional repression by microRNAs (miRNAs); (iv) release of soluble TLRs acting as soluble
decoy; (v) intracellular inhibitors; and (vi) membrane-bound blockers of TLR signaling pathways
after TLR engagement by its ligands [127]. Preclinical and clinical studies have evaluated Eritoran
tetrasodium, a compound that interferes with TLR4/MD-2/LPS, inhibiting the LPS-induced release
of TNF-α, IL-β and IL-6, thus limiting excessive inflammation associated with TLR4 activation,
as a potential therapeutic for sepsis. However, as far as we know, the efficacy of Eritoran has never
been tested in PD [128]. Ibudilast is a cyclic nucleotide phosphodiesterase inhibitor as well as a TLR4
antagonist which is currently used as a bronchodilator, vasodilator and anti-inflammatory agent
for the treatment of asthma, post-stroke dizziness and ocular allergies in Japan and other Asian
countries [129]. Considering its documented ability on up-regulating the anti-inflammatory cytokines
(i.e., IL-10, IL-4) and promoting the production of neurotrophic factors (i.e., GDNF, NGF, NT-4), it has
been recently tested in an animal model of PD. Ibudilast showed an anti-inflammatory response
via the modulation of glial cell activity, attenuation of TNF-α expression and induction of GDNF.
However, these ibudilast-mediated beneficial events were not a sufficient protection in the acute phase
of injury [129]. Anti-TLR2 antibodies have been tested in clinical studies for treating severe sepsis and
inflammation. It is conceivable that these TLRs signaling inhibitors could modulate the progression of
the severity of PD.
MicroRNAs (miRNAs) are recognized to be involved in the control of disease progression. Very
recently it has been shown that the overexpression of miR-22 was induced by microbiota-produced
butyrate [130]. The study of gut microbiota–miRNA interplay has disclosed that the gut microbiota
may affect the host by producing miRNAs, and on the other side the gut microbiota might be regulated
by host-secreted miRNAs [131]. An interesting study has highlighted that gut microbiota modulates
miRNA-associated mRNA expression patterns in the hippocampus of germ-free mice. In addition,
these transcriptional changes are sex-dependent, pointing towards a divergence between molecular
pathways that control the gut-brain axis [132]. Some new findings advocate that miRNAs control
the TLR-signaling pathway at several stages, including the regulation of TLR mRNA expression,
direct activation of the receptor, binding to TLR or TLR-specific signaling pathway components
and TLR-induced transcription factors and functional cytokines [133]. The research of the possible
relationships between exosomes, miRNAs and TLRs in the nervous systems is still in its infancy.
However, we can hypothesize that miRNAs entering the cells via exosomes may finely tune the
activation of TLRs. Furthermore, TLR tolerance, a hyporesponsive state of the receptor, characterized
by reprogramming of TLR-mediated signal transduction, may be achieved by intracellular delivery of
miRNA using exosomes.
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Potential pharma- and/or nutraceutical modulators of the microbiota-gut-brain axis as well as
TLRs signaling in the progression of pathology in PD are summarized in Table 1.
Table 1. Pharma- and/or nutraceuticals as potential modulators of the microbiota-gut-brain axis and
Toll-like receptors (TLRs) signaling in the progression of pathology in Parkinson’s disease (PD).
Modulator Influence on Microbiota-Gut-Brain Axis Potential TLRsTarget References
Dietary supplements
Docosahexaenoic acid
(DHA)
Reduction of oxidative stress by improving neuronal
mitochondrial dysfunction TLR2, TLR4 [104,108,134]
Panax Notoginseng (NotoG) Suppression of microglial activation and reduction of IL-6and TNF-α release TLR4 [110]
Sylimarin Antioxidant and neuroprotective effects (salvaging offree radicals) TLR4 [111]
Probiotics
L. rhamnosus (JB-1) Modulation of GABAA and GABAB receptors in the brain TLR1, TLR2, TLR6 [118,135]
Lactobacillus casei Shirota Decrease of visceral pain and bloating; improvement ofstool consistency TLR1, TLR2, TLR6 [120,135]
Lactobacillus reuteri Improvement of bowel movement and increase of thefrequency of evacuation TLR1, TLR2, TLR6 [121,135]
Prebiotics
Fructo oligosaccharides
(FOS) Increase of BDNF expression in the hippocampus TLR2, TLR4 [73,124,135]
Galacto oligosaccharides
(GOS) Improvement of villus surface area in the small intestine TLR1-TLR13 [135,136]
Short-chain fatty acids
(SCFA)-Butyrate Maintenance of colonic epithelium integrity TLR1, TLR2, TLR6 [135,137]
Antibiotics
Rifaximin Treatment of small intestinal overgrowth TLR4 [125]
Mynocicline Neuroprotective effect on nigrostriataldopaminergic neurons TLR4 [126]
TLRs modulators
Eritoran tetrasodium Inhibition of LPS-induced proinflammatorycytokine release TLR4 [128]
Ibudilast
Improvement of anti-inflammatory cytokine release,
modulation of glial cells activity and induction of
GDNF expression
TLR4 [129]
MiR-22 Induced by butyrate-producing commensal bacteria TLR1, TLR2, TLR6 [130,135]
9. Conclusions
Currently, no treatment for curing PD is available. Levodopa is the primary anti-parkinsonian
medicine, which exerts a symptomatic effect but does not stop neurodegeneration and is ineffective
on non-motor dysfunctions. Therefore a better understanding of the interaction between TLRs and
the enteric microbiota-gut-brain axis might help to generate novel insights into PD pathology, as well
as lead to new therapeutic strategies, such as pharmacological or dietary approaches. There is now
mounting evidence for the beneficial effects of probiotics on ameliorating intestinal epithelial barrier
function, stimulating host homeostasis of the mucosal immune system and preventing pathogenic
microbial growth and colonization. Considering that TLR ligands derived from probiotics could
suppress inflammation partially through the production of anti-inflammatory cytokines, the use of
probiotics, or prebiotics or synbiotics, appears to be an interesting strategy, given their huge potential
as medications or prophylactic agents against neurodegeneration. This potential stems from the fact
that they exert a beneficial effect on the composition and function of the gut microbiota, restoring the
complex dialogue between enteric microbes and the host, and ultimately reestablishing a balanced
gut-brain axis.
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